This chapter provides a general overview of considerations when economic analyses are reported for the management of patients with rectal cancer. Although we have included an assessment of selected European, Australasian and North American variations in reported series as they pertain to rectal cancer for the use of radiotherapy, adjuvant-neoadjuvant chemotherapy and multimodality therapy, we describe more the pitfalls in the interpretation of comparative economic data assessing rectal cancer care.
|Title of host publication
|Comprehensive Rectal Cancer Care
|Springer International Publishing
|Number of pages
|Published - 1 Jan 2019